Business
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi’s leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond. This
About this update from Tevogen Bio Holdings Inc.
[{"type":"image","alt":"Tevogen Bio Inc","displaySize":"","headline":null,"caption":"Tevogen Bio Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/d5ee464a32ca03b94210decff93ef50f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mr9JIiP8DWMjyCn1Y2wXjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d5ee464a32ca03b94210decff93ef50f","width":300,"height":45}},"lazy":false},{"type":"text","content":"WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi’s leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond.","length":495,"tagName":"p"},{"type":"text","content":"This announcement coincides with a significant milestone in Tevogen’s growth, the appointment of David E. Banko, as Global Head of Government Affairs and Patient Access. Mr. Banko’s focus will include advancing patient access, engaging with public and private payers, and securing coding, coverage, and reimbursement pathways, all essential to the company’s commercialization strategy.","length":385,"tagName":"p"},{"type":"text","content":"Mr. Banko’s appointment along with the Company’s recent developments supports the previously announced topline forecast of $1 billion in launch year for Tevogen Bio Oncology and nearly $1 billion for Tevogen Bio Specialty Care.","length":227,"tagName":"p"},{"type":"text","content":"About Tevogen Bio","length":17,"tagName":"p"},{"type":"text","content":"Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility throu...